Editorials

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
Department of Internal Medicine III, Ulm University, Germany
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, University of Barcelona, Spain
Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden;Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
Division of Experimental Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS Instituto Scientifico San Raffaele, Milan, Italy
Vol. 101 No. 3 (2016): March, 2016 https://doi.org/10.3324/haematol.2015.139246